# Lentiviral Gene Therapy (Zamtocabtagene Autoleucel) LTFU

> **NCT06116110** · — · RECRUITING · sponsor: **Miltenyi Biomedicine GmbH** · enrollment: 150 (estimated)

## Conditions studied

- Non Hodgkin Lymphoma

## Interventions

- **OTHER:** Long-term Follow-Up

## Key facts

- **NCT ID:** NCT06116110
- **Lead sponsor:** Miltenyi Biomedicine GmbH
- **Sponsor class:** INDUSTRY
- **Phase:** —
- **Study type:** OBSERVATIONAL
- **Status:** RECRUITING
- **Start date:** 2024-05-15
- **Primary completion:** 2039-12-01
- **Final completion:** 2039-12-01
- **Target enrollment:** 150 (ESTIMATED)
- **Last updated:** 2024-11-20


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06116110

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06116110, "Lentiviral Gene Therapy (Zamtocabtagene Autoleucel) LTFU". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT06116110. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*